EU-AIMS is the largest single grant on Autism in the world, and the largest in any mental health disorder in Europe. EU-AIMS involves a novel collaboration between organisations representing affected individuals and their famillies (Autism Speaks), academia and Industry who for the first time in the world have come together to develop the infrastructure underpinning new treatments for autism.

The project European Autism Interventions – A Multicentre Study for Developing New Medications, led by Roche and King's College London is partnered with a selected group of major global pharmaceutical companies, composed of Roche, Eli Lilly, Servier, Janssen Pharmaceutica, Pfizer and Vifor Pharma, and the world’s leading Autism Research Charity Autism Speaks (USA).

The academic partners contribute essential skills & knowledge crucial toward the success of this enterprise. Those involved include:

King’s College London (UK)

Central Institute of Mental Health Mannheim (Germany)

Radboud University Nijmegen Medical Centre (The Netherlands)

Cambridge University (UK)

University Medical Center Utrecht (The Netherlands)

Biozentrum, University of Basel (Switzerland)

Institut Pasteur (France)

Max-Planck-Gesellschaft (Germany)

European Molecular Biology Laboratory (Germany)

Karolinska Institutet (Sweden)

Birkbeck, University of London (UK)

Institute of Education (UK)

University "Campus Bio-Medico” (Italy)

University Ulm (Gemany)

Commissariat à l'Energie Atomique et aux Energies Alternatives (France)

Aiding this ground-breaking project are two further pharmaceutical small and medium-sized enterprises (SME), deCode Genetics (Iceland) and NeuroSearch (Demark) who will contribute to the success of EU-AIMS, while the SME GABO:mi (Germany) will have the complex task of managing the multi-national project.

The research of EU-AIMS receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115300, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), from the EFPIA companies’ in kind contribution and from the Autism Speaks resulting in a total of €29.6 million.